Honkamp Krueger Financial Services Inc. Has $428,000 Stock Position in Becton Dickinson and Co (NYSE:BDX)

Honkamp Krueger Financial Services Inc. lifted its stake in Becton Dickinson and Co (NYSE:BDX) by 4.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,574 shares of the medical instruments supplier’s stock after acquiring an additional 60 shares during the period. Honkamp Krueger Financial Services Inc.’s holdings in Becton Dickinson and were worth $428,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. AE Wealth Management LLC grew its stake in shares of Becton Dickinson and by 19.4% in the third quarter. AE Wealth Management LLC now owns 5,127 shares of the medical instruments supplier’s stock worth $1,297,000 after acquiring an additional 833 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Becton Dickinson and by 0.6% during the third quarter. Russell Investments Group Ltd. now owns 696,570 shares of the medical instruments supplier’s stock worth $174,650,000 after buying an additional 4,237 shares in the last quarter. MAI Capital Management boosted its stake in Becton Dickinson and by 43.4% during the second quarter. MAI Capital Management now owns 3,215 shares of the medical instruments supplier’s stock worth $810,000 after buying an additional 973 shares in the last quarter. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in Becton Dickinson and by 0.8% during the third quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 6,366 shares of the medical instruments supplier’s stock worth $1,610,000 after buying an additional 51 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Becton Dickinson and by 7.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 63,248 shares of the medical instruments supplier’s stock worth $15,999,000 after buying an additional 4,487 shares in the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

A number of equities research analysts have weighed in on the stock. Barclays downgraded shares of Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 price target on the stock. in a research note on Wednesday, January 8th. JPMorgan Chase & Co. lifted their price target on shares of Becton Dickinson and from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. KeyCorp decreased their price target on shares of Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. Stifel Nicolaus lifted their price target on shares of Becton Dickinson and from $275.00 to $295.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Finally, Morgan Stanley lifted their price target on shares of Becton Dickinson and from $261.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and an average target price of $277.70.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 33,365 shares of Becton Dickinson and stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $271.28, for a total transaction of $9,051,257.20. Following the completion of the transaction, the chief executive officer now directly owns 254,312 shares of the company’s stock, valued at $68,989,759.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Vincent A. Forlenza sold 11,626 shares of Becton Dickinson and stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $265.57, for a total value of $3,087,516.82. Following the transaction, the chief executive officer now directly owns 225,393 shares of the company’s stock, valued at $59,857,619.01. The disclosure for this sale can be found here. Over the last three months, insiders have sold 91,231 shares of company stock valued at $24,787,690. Company insiders own 0.12% of the company’s stock.

Shares of NYSE BDX opened at $277.30 on Thursday. The stock has a market cap of $74.64 billion, a PE ratio of 23.74, a PEG ratio of 1.97 and a beta of 1.07. The business has a fifty day moving average of $267.92 and a two-hundred day moving average of $256.09. Becton Dickinson and Co has a 52-week low of $221.47 and a 52-week high of $279.62. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.72 and a current ratio of 1.18.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.30 by $0.01. The company had revenue of $4.58 billion during the quarter, compared to analysts’ expectations of $4.57 billion. Becton Dickinson and had a return on equity of 15.52% and a net margin of 6.84%. The business’s revenue was up 4.1% on a year-over-year basis. During the same period last year, the business earned $2.93 earnings per share. Analysts predict that Becton Dickinson and Co will post 12.57 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Tuesday, December 10th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 9th. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.14%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.05%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What does cost of debt say about a company’s financial health?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.